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Resumo 
 
A doença de Parkinson é uma doença neurodegenerativa com uma etiologia complexa, 
incluindo fatores genéticos e ambientais. Em todo o mundo, mais de seis milhões de pessoas 
sofrem com a doença. A mesma é considerada uma sinucleinopatia, caracterizada pela 
acumulação de corpos de Lewy e degeneração de neurônios dopaminérgicos principalmente 
no mesencéfalo. 
O gene codificante da proteína tau associada aos microtúbulos está presente no cromossomo 
17q21.31. Juntamente com outros 18 genes, está localizado em um num desequilíbrio de 
ligação de 952 kb existente em dois haplótipos. O haplótipo em orientação direta é chamado 
H1 e o inverso, H2. O haplótipo MAPT mais comum, H1, tem sido associado às tauopatias, 
bem como à doença de Parkinson. Também foi demonstrado que o polimorfismo de 
nucleótido único rs8070723 do haplótipo H1 está associado a um risco aumentado a doença. 
A proteína Tau possui 6 isoformas, uma expressão mais elevada de da sua isoforma 4R tau 
pode influenciar o desenvolvimento de proteinopatias como tauopatias e sinucleinopatias. 
Várias alterações em funções celulares estão associadas à patogênese da doença de 
Parkinson idiopática. O haplótipo de risco MAPT pode aumentar a suscetibilidade para 
neurotoxinas e fatores ambientais. Este projeto visa investigar se o risco de polimorfismo de 
nucleótido único rs8070723 do haplótipo H1 de MAPT pode potencializar neurotoxicidade 
causada por estressores bioquímicos associados à doença de Parkinson. 
As “human fetal neural progenitor cells” derivadas do mesencéfalo de espécimes com 
diferentes haplótipos de MAPT foram tratadas com rotenona, epoxomicin, wortmannin e H2O2. 
A susceptibilidade às toxinas foi analisada através do ensaio de lactato desidrogenase. 
Observamos que as células com o haplótipo H1/H1 apresentaram maior susceptibilidade aos 
estressores bioquímicos quando comparadas às células com o haplótipo H2/H2. Além disso, a 
expressão de tau analisada 1 e 2 semanas após a diferenciação mostrou que principalmente 
três isoformas de Tau foram expressas: 2N3R, 1N4R e 0N3R. No entanto, são necessárias 
mais experimentações para confirmar esses dados. 
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Abstract 
Parkinson’s disease is a neurodegenerative disorder with a complex etiology, including genetic 
and environmental factors. Worldwide, over six million people suffer from the disease. It is 
considered a synucleinopathy, characterized by accumulation of Lewy bodies and 
degeneration of dopaminergic neurons primarily in the midbrain.  
The coding gene of microtubule associated protein tau is present on chromosome 17q21.31. 
Together with 18 other genes it is located in a 952 kb linkage disequilibrium that exists in two 
haplotypes. The haplotype in direct orientation is named H1 and the inverted, H2. The most 
common MAPT haplotype, H1, has been linked to tauopathies as well as Parkinson’s disease. 
It has also been shown that the single nucleotide polymorphism rs8070723 of the H1 haplotype 
is associated with an increased risk for the disease. Tau protein has 6 isoforms, a higher 
expression of the 4R tau isoform might influence the development of proteinopathies such as 
tauopathies and synucleinopathies.  
Several alterations of cellular functions are associated with the pathogenesis of idiopathic 
Parkinson’s disease. The MAPT risk haplotype might increase susceptibility for neurotoxins 
and environmental factors. This project aims to investigate if the risk single nucleotide 
polymorphism rs8070723 of the MAPT haplotype H1 might potentiate neurotoxicity caused by 
biochemical stressors associated with Parkinson’s disease.  
Human fetal neural progenitor cells derived from the midbrain of specimens with different 
MAPT haplotypes were treated with rotenone, epoxomicin, wortmannin and H2O2. Toxin 
susceptibility was analysed via the lactate dehydrogenase assay.  
We observed that cells with the H1/H1 haplotype displayed a higher susceptibility towards 
biochemical stressors when compared to cells with H2/H2 haplotype. In addition, the 
expression of tau analysed 1 and 2 weeks post differentiation showed that mainly three Tau 
isoforms were expressed: 2N3R, 1N4R and 0N3R. However, further experiments are 
necessary to confirm this data. 
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1 Introduction 
1.1 Parkinson’s disease 
Over six million people suffer from Parkinson disease (PD), or idiopathic Parkinson 
syndrome (IPS), placing this disease as the second most common neurodegenerative 
disease worldwide [6], [39]. PD is a complex neurodegenerative disorder with genetic and 
environmental factors as its etiology [13]. Advanced age is an important factor to this 
disorder; the population over 65 years of age is 1–2% affected by PD and it is estimated that 
the number of cases will rise in the following years [57]. 
The main characteristic of this disease is the degeneration of dopaminergic neurons in the 
substantia nigra pars compacta and its classical parkinsonian motor symptoms [30], [50]. 
Most patients are only diagnosed with PD after the manifestation of motor symptoms, which 
include resting tremor, slowness of voluntary movement, rigidity and postural instability [31], 
[57]. At this point, up to 80 % of dopaminergic cells in the nigro-striatal system are estimated 
to be lost [57]. Apart from this, Parkinson’s patients also manifest non-motor dysfunctions, 
some of which precede the motors symptoms by more than a decade [30]. IPS’s non motor 
symptoms include anosmia, REM sleep behavioural disorder, depression and forms of 
dementia might also be observed [69]. IPS is a progressive degenerative illness of the 
human nervous system that manifests itself clinically after the pathology has already 
reached an advanced stage [7]. 
Lewy Neurites (LNs) and Lewy Bodies (LB) are intracytoplasmic inclusions with a spindle or 
a globular form, respectively [14]. Their presence lead to the loss of dopaminergic neurons in 
the substantia nigra pars compacta and other brain regions [31]. The major component of 
LNs and LB is aggregated ɑ-synuclein, a presynaptic protein expressed also in 
dopaminergic neurons which function involves the maintenance of synaptic vesicles 
necessary for neurotransmission [14], [60]. The ɑ-synuclein aggregates are often present 
years before the diagnosis of PD [7]. The Lewy Bodies, in the pre-symptomatic stages of 
PD, outset in the medulla oblongata, in the pontine tegmentum and in the olfactory 
bulb/anterior olfactory nucleus [69]. When it spreads to the midbrain, the firsts motor 
symptoms start to occur [7]. In the end stage, when the disease reach the neocortex, a 
variety of clinical manifestations such as dementia and psychosis start to occur [7], [69]. 
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The etiology of PD can be characterized by two different causes: inherited, which affects 
between 10 to 15 % of PD patients and non- inherited, also called idiopathic Parkinson 
syndrome (IPS) [76].  
Mutations in several genes have already been associated to autosomal dominant (SNCA, 
LRRK2 and VPS35) and autosomal recessive (PARK-2, PARK-7, DJ-1 and PINK-1) forms of 
PD [13], [76]. Mutations in the SNCA gene, which express the α-synuclein protein, are 
associated with premature cognitive impairment and might cause symptoms of early 
dementia [20]. On the other hand, the autosomal recessive genes PARK-2 and PINK-1 tend 
to cause severe motor symptoms with less cognitive impairment [20].  
Cellular impairments such as oxidative stress and mitochondrial, proteasomal and 
autophagic dysfunctions are suggested to contribute to IPS [40]. In combination with genetic 
variants, environmental factors might increase the risk for Parkinson’s disease [4]. Multiple 
genome-wide association studies (GWAS) have identified small risk loci that might play a 
crucial role for the development of neurodegenerative disorders such as PD [13]. 
Interestingly, beside SNCA, MAPT was the second most important risk factor [13].  
Until this day, there is no effective treatment to slow or stop the progression of PD [69]. The 
standard therapy with drugs that increase intracerebral dopamine concentrations or 
stimulate dopamine receptors, such as L-Dopa, a dopamine precursor, only target the 
correction of motor disturbances [30], [69].  The development of more effective drugs is a 
major goal of Parkinson’s disease research, therefore comprehension of underlying 
pathophysiological mechanisms are very important [6]. 
1.2 MAPT, tau and the idiopathic Parkinson syndrome 
Neurodegenerative diseases are classified on the basis of their protein substrates [55]. The 
two major groups are the synucleinopathies, linked to α-synuclein, Lewy bodies and Lewy 
neurites and the tauopathies, related to microtubule-associated protein TAU [54]. Idiopathic 
Parkinson’s syndrome is the most common synucleinopathy. However, both SNCA and 
MAPT genes are known to contribute with PD susceptibility [3], [78], [82].  
The tau protein was discovered in 1975 and it was one of the first microtubule- associated 
proteins to be described [37]. Tau is a natively unfolded protein and associated to the 
cytoskeleton of the nervous system [12], [32]. Aggregates of tau filaments and its deposition 
in neuronal or glial fibrillary inclusions define the pathological characteristics of tauopathies 
[1]. 
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Human tau protein is encoded by the MAPT gene, located on chromosome 17q21 and 
comprises 16 exons [33]. Alternative splicing of the exons 2, 3 and 10 generate six different 
isoforms of the protein (Figure 1) [37]. The isoforms differ in the number of amino acids 
inserted at the N-terminal region (N) and the amount of microtubule repeats (R), creating the 
following isoforms: 2N4R, 1N4R, 0N4R and 2N3R, 1N3R, 0N3R [20]. Tau isoforms length 
range from 352 to 441 amino acids (36.8 to 45.9 kDa) [47]. mRNAs missing exon 10 
generate the 3R isoform meanwhile mRNAs including exon 10 encode the 4R tau [47]. In the 
developing brain, the 3R tau isoforms are dominant, while in an adult brain all six tau 
isoforms can be found [11]. The ratio of 4R:3R tau expression in a healthy adult brain is 
approximately equal [34]. Meanwhile the ratio between the 0N, 1N and 2N is 37:57:9 [53]. 
Some mutations may affect the splicing of tau mRNA, resulting in increased expression of 
the 4R tau isoforms compared to 3R tau isoforms [35]. Imbalance between tau isoforms 
might be related to tauopathies [1].  
 
 
Figure 1: Tau mRNAs after splicing. The six tau isoforms are generated by alternative splicing and differ from each other in the 
number of amino acids inserted at the N-terminal region (N) and the amount of repeats (R). Adapted from [77].   
Phosphorylated tau is necessary to control the equilibrium between tau and microtubules 
[59]. Although tau phosphorylation is a normal and reversible process, an increased MAPT 
expression can disrupt the structure of microtubules by the accumulation of misfolded and 
abnormal phosphorylated tau protein, which in turn may lead to tauopathies [10], [12]. 
The MAPT gene possesses an ancestral inversion polymorphism which generates a 1.8 Mb 
region of linkage disequilibrium (LD) [10], [49]. This inversion leads to different haplotypes 
with distinct orientations. H1 which has direct orientation, is evolutionary dynamic and 
composed of a variation of single nucleotide polymorphisms (SNPs) [46], [49].  The second 
haplotype, H2, has an inverted orientation of ~970 kb. It is uncommon and relatively 
invariant (Figure 2) [77]. The LD of the H2 haplotype might have been the result of a single 
event or by a chromosome rearrangement or by a limited intermixing with a predating 
population [21].  
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Figure 2: MAPT gene locus and its haplotypes. Tau protein is encoded by the MAPT locus on chromosome 17. The haplotypes 
H1 and H2 differ from each other through single nucleotide polymorphisms (SNP) and are among other genes within complete 
linkage disequilibrium. The H2 haplotype has an inversion polymorphism. Adapted from [77].   
The H1 haplotype, and most specifically the H1c variant, has been associated not only to an 
increased risk of neurodegenerative disorders such as tauopathies but also with an higher 
risk of Parkinson’s disease [27], [49], [54], [73]. It was also suggested that the H2 haplotype 
has a protective effect on the development of PD [65]. Furthermore, the H1c haplotype 
increases the relative levels of 4R tau isoform due to promoting higher exon 10 incorporation 
[46]. The MAPT gene was identified via GWAS as the second most important risk factor for 
IPS (Figure 3) [19]. 
 
Figure 3: Distinct SNPs on the H1 haplotype associated with different neurodegenerative disorders. SNPs within the intronic 
regions of the MAPT gene [10]. The marked SNP rs8070723 is linked to a higher risk for idiopathic Parkinson syndrome [19]. 
Adapted from [9]. 
In neurological disorders an interaction between pathogenic proteins is common, resulting in 
a disturbance of their normal function through a downstream activity modulation [59]. A 
genetic relation between the proteins α-synuclein and tau in IPS was previously reported 
[59]. 
The risk genotypes MAPT and SNCA when expressed individually have a marginal effect on 
PD development, however, the interaction between those two genes may have a higher 
influence on this event [24]. Studies suggest that the links between tau and α-synuclein are 
5 
 
functional and pathological [73]. α-synuclein influences tau phosphorylation and its 
fibrillization, inducing a risk factor for IPS [73]. IPS progression can be stimulated by the 
formation of hybrid α-synuclein and tau oligomers which are able to accelerate the 
oligomerization process [59]. 
1.3 Environmental factors related to the idiopathic Parkinson 
syndrome 
Another important risk factor for the development of PD are environmental influences. 
Factors as pesticide exposure, head injury, use of β-blockers among others, were already 
referred as risks factors [30]. On the other hand, tobacco smoking, coffee drinking were 
considered protective factors to PD development [30]. Induced cell death by apoptotic 
processes involving a cascade of events such as oxidative stress, inflammation, 
mitochondrial dysfunction and excitotoxicity were also suggested as risks factor for PD 
progress [48]. 
 
 
Figure 4: Examples of cellular dysfunctions observed in the idiopathic Parkinson syndrome (clear blue box) caused by its 
respective neurotoxins (red letters) that eventually lead to cell death (dark blue box).  
During this master thesis we monitored the effects of four neurotoxins: epoxomicin, 
wortmannin, rotenone and H2O2 in order to mimic the environmental influence in human 
midbrain derived neural progenitor cells with the MAPT haplotypes in homozygosity. 
Neuronal 
cell death 
Mitochondrial 
impairment 
Oxidative 
stress 
Impaired 
autophagy 
Impaired UPS 
Rotenone 
H2O2 
Wortmannin 
Epoxomicin 
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1.3.1 Mitochondrial inhibition and rotenone 
Also, environmental factors are associated with IPS, as an example is the exposure to 
pesticides [2]. Rotenone is a compound commonly used as a pesticide which acts as an 
inhibitor of the mitochondrial complex I [2], [70]. Rotenone treatment also leads to an 
increased ROS production [26]. Since dopaminergic neurons already have a higher ROS 
generation as a result from dopamine metabolism, they are more vulnerable to oxidative 
stress and therefore toxins like rotenone [17]. Therefore, to induce mitochondrial impairment, 
rotenone was employed in our cell model. 
1.3.2 Proteasome inhibition and epoxomicin 
In eukaryotic cells, the degradation of abnormal proteins is situated in the cytoplasm, 
nucleus and the endoplasmic reticulum by the ubiquitin-proteasome system (UPS) [48]. A 
failure in this system is suggested to play a role in PD’s etiology [48]. When the UPS fails, for 
example due to defects in the 20S proteasome, it can lead to accumulation and aggregation 
of proteins. Protein accumulation and aggregation of α-synuclein is a hallmark of PD and 
may cause neurotoxicity [41]. One example of this failure is the possible formation of the 
Lewy bodies in dopaminergic neurons of the substantia nigra pars compacta, a characteristic 
of PD [41]. The chosen toxin to inhibit the UPS in our cell lines, epoxomicin, is a specific 
proteasome inhibitor which binds to the 20S proteasome, thus inhibiting irreversibly four 
catalytic subunits. 
1.3.3 Autophagy inhibition and wortmannin 
Another protein and organelle degradation pathway is the autophagy-lysosomal pathway 
(ALP) [18], [79].  Autophagy is characterized by the degradation of cytoplasmic proteins and 
organelles via lysosomal enzymes aiming the recycling of cellular components or the 
prevention of the accumulation of those structures [84]. To sequester cytosolic 
compartments, organelles, proteins and lipids, autophagosomes are formed. The 
autophagosomes fuse in later stages with lysosomes or late endosomes, which contain 
stored degrading enzymes [18]. 
Since aggregated proteins can’t penetrate the proteasome barrel, in IPS, the aggregated ɑ-
synuclein from the Lewy bodies are degraded via ALP, while its soluble forms might be 
degraded via UPS [79]. Wortmannin disturbs the autophagosome formation via inhibition of 
the assembly of the double membrane, which eventually forms the autophagic vesicle [84]. 
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Hence, wortmannin was used to achieve autophagic impairment from the start of the 
autophagy process. 
1.3.4 Oxidative stress and H2O2 
Reactive oxygen species (ROS), such as hydrogen peroxide (H2O2) and superoxide radicals, 
are generated by the mitochondria during mitochondrial respiration as a by-product of 
oxidative phosphorylation [16]. 
Although the brain is very sensitive to oxidative damage, about 20% of the oxygen resources 
of the organism are consumed by it [15]. ROS production in the neurons is extremely high 
due to a high oxygen output rate, a limited availability of antioxidant and a high amount of 
fatty acids that are easily unsaturated [15], [39]. ROS oxidize lipids, DNA, RNA and proteins 
either directly or indirectly [15]. A balance between ROS production and degradation is 
necessary to the homeostasis [16]. Cell damage and possible death can be promoted by a 
disrupted balance which allows ROS accumulation and oxidative stress [16]. H2O2 was 
employed in our cell model to induce oxidative stress. 
1.4 Cellular model to investigate the idiopathic Parkinson 
syndrome 
In order to investigate the etiology of IPS and other neurodegenerative disorders, different 
human cellular models are frequently used. To explore the molecular mechanisms of IPS, 
human neuronal cells are the best choice [56].  
To this master thesis, the fetal human midbrain neural progenitor cells (hmNPCs) were used. 
HmNPCs are isolated from aborted fetuses after 10-14 weeks after fertilization followed by 
preparation of region specific cell lines. These tissue- specific precursors are able to self-
renewal and can be cultured for months without closing their potential of differentiation into 
neurons and glial cells [45], [66]. Furthermore, hmNPC are able to differentiate into 
dopaminergic neurons, this ability creates a promising tool to IPS research, either for the 
improvement of cellular models to the disease etiology study or for cell therapies for 
Parkinson’s patients [45], [80]. HmNPCs are a valuable reference model for neuronal cells 
derived from induced pluripotent stem cells too. But most importantly, hmNPC give us the 
opportunity to investigate and compare cell lines with different MAPT haplotypes. 
 
8 
 
2 Objectives 
Aim of the present master thesis is to explore different mechanisms by which the risk MAPT 
haplotype, H1/H1, may contribute to the development of IPS. Therefore, different hmNPC 
lines with the MAPT haplotypes H1/H1 and H2/H2 for the risk SNP rs8070723, were 
submitted to neurotoxic treatments aiming to induce cellular dysfunctions, such as induction 
of oxidative stress, mitochondrial and proteasome impairment and autophagy inhibition.  
The same cell line with the same haplotypes mentioned above, were also differentiated for 
distinct periods of time aiming to chart the expression of the tau isoforms. 
During this project the following points were investigated: 
1. Induction of neurotoxicity to hmNPC. 
2. Comparison of toxic impact between different MAPT genotypes. 
3. Comparison between the expression of the tau isoforms after 1 and 2 weeks of cell 
differentiation in different hmNPC haplotypes via Western blot. 
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3 Materials and Methods 
3.1 Human midbrain neural progenitor cell culture   
3.1.1 Ethics  
All experiments performed in this master thesis were approved by the ethics committee of 
the University of Leipzig and the Technical University of Munich, Germany in accordance 
with all state and federal guidelines. The chosen cell lines were prepared from aborted 
fetuses posterior to the mother’s consent. 
3.1.2 Preparation of hmNPCs  
HmNPCs have been generated as described by Moon et al. [45]. To guarantee tissue 
specificity, the cells were analysed for dopamine transporter expression by flow cytometry in 
order to characterize them as mesencephalic: at least 0.5% of the cells had to be positive for 
dopamine transporter expression for mesencephalic classification. This result was confirmed 
by the expression of tyrosine hydroxylase via Western blot, as described by Milosevic et al. 
[43], [44]. Furthermore, the expression of markers of dopaminergic neurons was assessed 
by RT-PCR [45]. 
3.1.3 Cultivation of hmNPCs 
The cells were cultured in Dulbecco's Modified Eagle's Medium/Ham’s F12 medium 
(HyClone, GE Healthcare, Little Chalfond, UK) containing 2 % B27® supplement minus AO 
(Thermo Fisher Scientific, Darmstadt, Germany), 0.1 % gentamicin (Thermo Fisher 
Scientific, Darmstadt, Germany), 0.1 % of the mitogens rhu-EGF and rhu-bFGF-2 
(Peprotech, Hamburg, Germany) and 0.1 % tocopherol and tocopheryl acetate (Sigma-
Aldrich, Taufkrichen, Germany). Cells were cultured as monolayers in cell t75 culture flasks 
(NUNC; Sigma) coated with poly-L-ornithin (Sigma-Aldrich, Taufkrichen, Germany) and 
human fibronectin (Millipore, Merck, Darmstadt, Germany) in a humidified incubator at 37°C 
with a reduced oxygen atmosphere of 3 %.  
3.1.4 Coating 
For coating, a 15 µg ml-1 poly-L-ornithin solution was applied to cell t75 culture flasks 
(NUNC; Sigma-Aldrich, Taufkrichen, Germany) and 24 or 96 wells plates and incubated for 
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3h at 37°C. The culture dishes were washed with 1x PBS, then incubated with a 4 µg ml-1 
human fibronectin solution (Millipore, Merck, Darmstadt, Germany) for 3h at 37°C. The flasks 
and plates were washed with PBS and stored at -80°C until use. 
3.1.5 Expansion of hmNPCs 
For expansion of the hmNPC lines, 6 million cells were seeded out and the medium was 
exchanged completely twice a week. The cells were passaged when a confluency of at least 
80 % was achieved. For passaging, the cells were detached with 1x Accutase® (PAN 
biotech, Aidenbach, Germany) by incubation for 30 minutes at 37°C. Cells were spun down 
at 1500 rpm, re-suspended in fresh medium and counted. For experiments, cells were 
seeded into pre- coated culture plates of different sizes. 
3.1.6 Differentiation of hmNPCs 
For cell differentiation, a neurobasal medium (Invitrogen) supplemented with 2 % B27® 
supplement minus AO (Thermo Fisher Scientific, Darmstadt, Germany), 1x GlutaMAX 
(Thermo Fisher Scientific, Darmstadt, Germany) and 100 µM dibutiryl c-AMP (Sigma-Aldrich, 
Taufkrichen, Germany) was used. The hmNPC were differentiated for 8 days prior to 
experimental read out. 
3.2 Toxin application    
To perform the toxin assays cell lines were seeded in 96 well plates at a density of 30.000 to 
35.000 cells per well in expansion medium until it reached at least 80 % confluency, around 
3 to 5 days after seeding. After achieving the expected confluency, the medium was 
changed to differentiation medium and the cells were differentiated for 8 days. At day 6 or 7 
of differentiation, depending on the applied toxin (Table 1), the medium was replaced by 100 
µl of new differentiation medium containing the diluted toxins (Figure 5). 
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Figure 5: Timeline of toxins application. 
Rotenone (Sigma-Aldrich, Taufkrichen, Germany) and epoxomicin (ApexBio technology 
LLC, Houston, USA) were received as powder meanwhile wortmannin (Sigma-Aldrich, 
Taufkrichen, Germany) was ordered as a solution. The toxins were dissolved in 
dimethylsulfoxide (DMSO) to the maximal soluble concentration as listed in Table 1. All stock 
solutions were stored at -80 °C. H2O2 (Sigma-Aldrich, Taufkrichen, Germany) did not require 
a first dilution, it was kept as ordered in a 30 weight percent solution in water, corresponding 
to a 9.1 M concentration, it was stored in the dark at 4 °C and the dilutions for the cell 
treatments were prepared freshly before use. The rotenone aliquots were only used once 
upon thawing. 
Substance 
name 
Dissolved in 
and dilution 
Treatment 
concentration 
Treatment 
duration 
Source 
Catalogue 
number 
Rotenone 
Dissolved in 
DMSO to 
100 mM; 
diluted 
further in 
medium. 
50 µM and 
100 µM 
24 hours 
Sigma 
Aldrich 
R8875 
Epoxomicin 
Dissolved in 
DMSO to 10 
mM; diluted 
further in 
medium. 
1 µM and 10 
µM 
48 hours 
ApexBio 
technology 
LLC 
 
A260 
Wortmannin 
Dissolved in 
DMSO to 10 
mM; diluted 
further in 
medium 
5 µM and 10 
µM 
48 hours 
Sigma 
Aldrich 
WS3144 
H2O2 
Stock at 30 
% or 9,1 M; 
diluted 
further in 
medium 
20µM  and 
40µM 
24 hours 
Sigma 
Aldrich 
16911 
Table 1: Toxins and their features used for experiments. 
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The rotenone stock was dissolved in the medium by the addition of 2 % DMSO, an additional 
UTC with 3 % DMSO was used for this toxin. The epoxomicin and wortmannin stocks were 
diluted 1:100 in culture medium, not exceeding an end concentration of 1 % DMSO. For this 
untreated control (UTC), DMSO without compound was diluted 1:100 resulting in 1 % DMSO 
in medium.  Depending on the compound’s toxicity, the chemicals were applied at day 6 and 
7 of differentiation and incubated for 48 and 24 hours, respectively. The cell viability was 
then determined at day 8 for all treatment conditions. 
3.3 Cell toxicity assay - LDH assay  
The acute cell toxicity was assessed by measuring the release of NADH into the medium. In 
the chosen protocol LDH turns over pyruvate to lactate by using up NADH. Therefore, the 
consumption of NADH is proportional to LDH available in the medium. 
The reaction buffer consisted in 100 mM of pyruvate (Sigma-Aldrich, Taufkrichen, Germany), 
10 mM NADH (Sigma-Aldrich, Taufkrichen, Germany), in 80 mM Tris/HCL (Carl Roth, 
Karlsruhe, Germany) and 200 mM NaCl (Sigma-Aldrich, Taufkrichen, Germany) with pH 7.2. 
The positive control was lysed by lysis buffer (Promega, Mannheim, Germany) for 40 min. 30 
µl supernatant of samples, positive and medium only (blank) wells were transferred to a new 
clear 96 well plate. 70 µl of the reaction buffer was added directly before measurement. The 
absorbance was measured immediately with the CLARIOstar microplate reader (BMG 
Labtech, Ortenberg, Germany) at 340 nm for the absorption of NADH and 420 nm as 
reference measurement for 10 x 30 sec cycles. The blank-corrected values from cycle 3 to 7 
were then used for linear regression and the calculation of the curves steepness as they 
correlate to the amount of released LDH. The lysis control represents the maximal possible 
LDH release correlating with maximal toxicity. All values were normalized to the lysis control. 
3.4 Western blotting 
The cell lines with different differentiation times were detached with 1x Accutase® (PAN 
biotech, Aidenbach, Germany) by incubation for 30 minutes at 37°C, spun down at 1500 rpm 
for 5 min and re-suspended in 100 µl of M-PER (Thermo Fisher Scientific, Darmstadt, 
Germany) with protease and phosphatase inhibitors (Roche, Mannheim, Germany) and 
maintained at -80°C until use. A BCA assay (Thermo Fisher Scientific, Darmstadt, Germany) 
was performed in order to determine the protein concentration of the samples. An internal 
protein standard was used as an internal control for the Western blot analysis. 
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3.4.1 Lambda Protein Phosphatase ( PP) 
Lambda Protein Phosphatase is a Mn2+ dependent protein phosphatase used to release 
phosphate groups from phosphorylated serine, threonine and tyrosine residues in proteins. 
20 µg of the above mentioned samples were treated with the Lambda Protein Phosphatase 
(Lambda PP) Kit by New England BioLabs (Frankfurt, Germany), following the 
manufacturer’s instructions. 20 µg of protein, MPER buffer, a master mix of 10x PMP Buffer 
& 10 mM MnCl2 and 1µl of Lambda Protein Phosphatase were mixed and incubated at 30°C 
for 3 h without shaking. The loading buffer, 4X laemmli, was added and the samples were 
boiled at 75°C for 10 minutes. Unless indicated otherwise, samples were kept on ice. 
3.4.2 SDS PAGE and blotting 
Proteins were separated by SDS PAGE. Therefore, samples were loaded in a bis-tris 10 % 
gradient sodium dodecyl sulfate (SDS) polyacrylamide gel (BioRad, Hercules, USA). Two 
ladders were loaded into the gel, 4 µl of ProSieve protein ladder (Biozym, Hessisch 
Oldendorf, Germany) and a 2 µl of tau ladder. Electrophoresis was performed using the 
following settings: 75 V for 10 minutes, then 160 V for 70 min. Proteins were then transferred 
onto a PVDF membrane (BioRad, Hercules, USA) by wet transfer at 35 V for 2 hours at 4°C. 
3.4.3 Blocking and Antibody staining 
The membrane was fixed with 3,75 % PFA (Sigma) and blocked with a solution of  3x 
rotiblock (Carl Roth) in TBST. Posteriorly, the membranes were incubated with the following 
antibodies: Polyclonal Rabbit Anti-Human Tau (DAKO, Agilent, Santa Clara, USA) and Anti-
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Antibody (Millipore, Merck, 
Darmstadt, Germany), respectively, at concentrations of 1:3000, followed by incubation with 
Peroxidase labelled anti rabbit IgG (Vecto laboratories, Maravai Lifesciences, San Diego, 
USA) at a 1:5000 concentration, and read out at Licor Odyssey FC (Lincoln, USA). 
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 Antibody Staining Dilution Company 
Catalogue 
number 
Primary 
antibody 
Polyclonal 
Rabbit Anti-
Human Tau 
Total tau 1:3000 DAKO A002401-2 
Primary 
antibody 
Anti-
Glyceraldehy
de-3-
Phosphate 
Dehydrogen
ase 
GAPDH 1:3000 Milipore Abs16 
Secondary 
antibody 
Anti rabbit 
IgG 
Peroxidase 
labelled anti 
rabbit IgG 
1:5000 Ab Vector PI-1000 
Table 2: Details from primary and secondary antibodies used at Western Blotting. 
3.5 Statistical analysis   
 With the objective of comparing the toxicity assays from different cell lines and their MAPT 
haplotypes, the data acquired from the LDH assay had to be normalized to the respective 
control based on the following equation:  
 
T is related to the percentage of LDH release when treated with the toxin and C the LDH 
release from the UTC. Its respective p values were calculated with the two-way analysis of 
variance (ANOVA) at the program GraphPad Prism 7 (GraphPad Software, San Diego, 
USA). The data is represented as mean ± SEM. 
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4 Results 
4.1 Comparison of the toxin susceptibility of the different 
haplotypes   
For each condition, 3 biological repeats with 4 technical repeats for the H1/H1 and H2/H2 
MAPT haplotypes were performed in hmNPC lines and statistically analysed by the two-way 
ANOVA test. For each MAPT haplotype, 2 different hmNPC lines were used, excluding the 
ones used in the H2O2 toxicity assay. Due to a change in protocol only one cell line per 
haplotype was used in the analysis. 
4.1.1 Rotenone treatment of the different haplotypes 
The cells were incubated with 50 µM and 100 µM rotenone for 24 h. The acute 
toxicity measured by LDH release was significantly higher in hmNPC lines bearing 
the H1/H1 haplotype when compared to hmNPC lines of the H2/H2 after 50 µM and 
100 µM rotenone application, p- value < 0.005 and < 0.0001 respectively. The cell 
toxicity at 50 µM rotenone was 9 % in the H1/H1 haplotype compared to -2 % to the 
H2/H2. While at the 100 µM concentration the difference between the haplotypes was 
19 % in H1/H1 and 2 % in H2/H2. These results are shown in Figure 6. 
 
Figure 6: Effect of 50 µM and 100 µM rotenone exposure for 24h in hmNPC lines with MAPT haplotypes H1/H1 and H2/H2. 
LDH release analysis was normalized to untreated controls to determine toxicity. Graph represent mean +SEM. n=8. 
Significance was calculated by two-way ANOVA: **p< 0.005 and ****p< 0.0001. 
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4.1.2 Epoxomicin treatment of the different haplotypes   
The hmNPC lines were incubated with epoxomicin in concentrations of 1 µM and 10 µM for 
48 h. The LDH assay revealed a highly significant difference of epoxomicin induced acute 
toxicity between hmNPC lines.  In concentrations of 1 µM and 10 µM the H1/H1 haplotype 
showed an increase of LDH release when compared to the H2/H2 p-value p< 0.0001 and p< 
0.0001, respectively. After application of 1 µM epoxomicin the LDH release for the H1/H1 
haplotype was 46 % and 17 % of the H2/H2 compared to the untreated control. The 10 µM 
epoxomicin treatment induced the release of LDH of 49 % in the H1/H1 haplotype and 19 % 
in the H2/H2 cell lines compared to the untreated control. Shown in figure 7. 
 
Figure 7: Effect of 1 and 10 µM epoxomicin exposure for 48h in hmNPC lines with MAPT haplotypes H1/H1 and H2/H2. LDH 
release analysis was normalized to untreated controls for determination of toxicity. Graph represent mean +SEM. n= 6. 
Significance was calculated by two-way ANOVA: ***p< 0.0001 and ****p< 0.0001. 
4.1.3 Wortmannin treatment of the different haplotypes     
The hmNPC cell lines were incubated with5 µM and 10 µM wortmannin for 48 h. No 
significant differences could be observed with the LDH assay between the haplotypes. The 
cell toxicity at 5 µM wortmannin was 14 % in the H1/H1 haplotype compared to 7 % to the 
H2/H2. In the 10 µM concentration the difference between the haplotypes was 19 % to 
H1/H1 and 13 % to H2/H2. As demonstrated in Figure 8. 
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Figure 8: Effect of 5 µM and 10 µM wortmannin exposure for 48h in hmNPC lines with MAPT haplotypes H1/H1 and H2/H2. 
LDH release analysis was normalized to untreated controls to determine toxicity. Graph represent mean +SEM. n= 7. 
Significance was calculated by two-way ANOVA; both values were nonsignificant. 
4.1.4 H2O2 treatment of the different haplotypes 
The hmNPC cell lines were incubated with H2O2 at concentrations of 20 µM and 40 µM for 
24h. After treatment with 20 µM H2O2 both haplotypes showed a small statistical significance. 
Meanwhile, after the treatment with a higher H2O2 concentration (40 µM), no significant 
differences were observed, as demonstrated at the Figure 9. The 20 µM concentration 
induced a cell toxicity of 65 % and 38 % respectively for the H1/H1 and H2/H2. Meanwhile 
the treatment with 40 µM H2O2 showed a cell toxicity of 70 % and 64 % to H1/H1 and H2/H2 
haplotypes. 
  
  
Figure 9: Effect of 20 and 40 µM H2O2 exposure for 24h on hmNPC lines with MAPT haplotypes H1/H1 and H2/H2. LDH 
release analysis was normalized to untreated controls to determine toxicity. Graph represent mean +SEM. n=4. Significance 
was calculated by two-way ANOVA: *p< 0.05  
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4.2 Expression of tau isoforms in different haplotypes 
In order to study the expression of different tau isoforms, we developed Western blot 
protocols for TAU isoforms involving treatment with Lambda phosphatase ( PP). The 
Western Blots were performed with different MAPT haplotypes (H1/H1, H2/H1 and H2/H2) 
and cell lines one and two weeks post differentiation. The protein was loaded in triplicates. 
The representative pictures of the Western blots are shown in figures 10 and 11. 
 
   
 
Figure 10: Western blot analysis of tau after 1 week of differentiation. Electrophoresis with the different hmNPC lines with 
distinct MAPT haplotypes: H1/H1 (3-5), H2/H1 (6-8) and H2/H2 (9-11); internal protein standard (12); tau ladder (2 and 13) and 
ProSieve protein ladder (1 and 14). The six recombinant human brain tau isoforms are shown in the first lanes, molecular 
masses of 36.8, 39.7, 40.0, 42.6, 42.9, and 45.9 kDa, respectively. All hmNPC samples were treated with  PP before the 
assay.  
 
 
  
Figure 11: Western blot analysis of tau after 2 weeks of differentiation. Electrophoresis with the different hmNPC lines with 
distinct MAPT haplotypes: H1/H1 (3-5), H2/H1 (6-8) and H2/H2 (9-11); internal protein standard (12); tau ladder (2 and 13) and 
ProSieve protein ladder (1 and 14). The six recombinant human brain tau isoforms are shown in the first lanes, molecular 
masses of 36.8, 39.7, 40.0, 42.6, 42.9, and 45.9 kDa, respectively. All samples were treated with  PP. 
Analysis of the dephosphorylated tau by  PP treatment enabled identification of the 
individual tau isoforms present in each sample. The protocol of the TAU isoform western 
blots was in progress at the end of this master thesis. Therefore, the results presented are 
not optimal and cannot be further evaluated. Briefly, in both blots we were able to observe 
mainly the expression of three tau isoforms: 2N3R, 1N4R and 0N3R.  
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5 Discussion 
5.1 Toxin treatment of the different haplotypes  
The H1 haplotype of the MAPT gene has been associated to an increased risk of 
Progressive Supranuclear Palsy and as the second most common risk factor for PD [19], 
[27].  
HmNPC lines bearing different MAPT genotypes create a promising tool for IPS studies and 
allow the opportunity to consider invariable unmodified human neural cell lines with distinct 
genetic backgrounds [45], [58]. Although there is no evidence about the pathogenic 
mechanism behind neurodegeneration in IPS patients, some cellular and molecular 
dysfunctions such as mitochondrial and ubiquitin- proteasome dysfunctions, inhibition of 
autophagy and oxidative stress were already related to the disease’s etiology [5], [48].  
We treated hmNPC lines with different MAPT haplotypes with rotenone, epoxomicin, 
wortmannin and H2O2 to mimic the cellular and molecular dysfunctions mentioned above for 
24 or 48h to measure the acute toxicity between the genotypes. It was hypothesized that the 
MAPT risk haplotype would suffer a higher impact after the toxins treatment, developing a 
greater susceptibility towards environmental toxins. After 8 days of differentiation and 
appliance of toxins for 24 or 48h, hmNPC were submitted to LDH assay revealing an 
increased toxicity of rotenone and epoxomicin of the H1/H1 compared to the H2/H2 
genotypes. The treatment with wortmannin, however, showed no significant statistical 
difference between the genotypes. 
5.1.1 Rotenone treatment 
As mentioned before, mitochondrial dysfunction is associated with IPS [53], based on that 
we treated the cells with rotenone, a mitochondrial complex I inhibitor. We incubated the 
cells with the toxin for 24h at the concentrations of 50 and 100µM. The results showed a 
significant difference in toxicity between the haplotypes.  
Taking into account the difference in cell toxicity via LDH assay, the chosen time point for 
the read out was accurate. We could also observe that just a small fraction of cells revealed 
a toxic feature after rotenone treatment. The hmNPC cells are unaltered human fetal neural 
progenitor cells derived from the midbrain. Moon et Schwarz characterized these cells and 
found between 25 and 30 % of NPC differentiate into the dopaminergic phenotype. 
Dopaminergic neurodegeneration caused by the mitochondrial complex I impairment is 
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believed to happen preferably via oxidative stress than mediated by a bioenergetic defect 
[60]. Considering that rotenone also increases ROS levels [26], the death of the 
dopaminergic subpopulation seems likely. On the contrary, the manifestation of 
mitohormesis [71], already reported for small concentrations of this toxin [85] might have 
contributed to cell survival of more robust neuronal subpopulations and glial cells. 
Taking into account the unspecificity of the LDH assay, an evaluation of mitochondrial 
function in neurons of the different haplotypes could be assessed by a mitochondrial 
potential assay (MMP). The MMP assay monitors changes to cells capacity to generate ATP 
by oxidative phosphorylation, indicating cell health or damage [51]. In addition, double 
immunofluorescence for dopaminergic and apoptotic markers could address the question, 
which cells undergo apoptosis after rotenone treatment. 
5.1.2 Epoxomicin treatment 
The cells were treated with 1 and 10 µM epoxomicin for 48h, a proteasome inhibitor, in order 
to test the influence of proteasomal dysfunction on the different hmNPC haplotypes [42]. 
epoxomicin inhibits the catalytic function of proteasome, thus impairing the UPS [42]. The 
LDH assays showed a significantly higher LDH release at the H1/H1 haplotype when 
compared to the H2/H2. It is suggested that the inhibition of the proteasome reduces the 
activity of the complex I and II of the mitochondria which influences the electron transport 
chain, the main source of ROS [68]. As consequence of the treatment with epoxomicin, the 
proteasome induces mitochondrial dysfunction and a higher level of ROS.  
5.1.3 Wortmannin treatment 
The cells were treated with the autophagy inhibitor wortmannin at 5 and 10 µM for 48 h in 
order to impair the autophagic-lysosomal pathway [84]. The differences between the 
haplotypes in wortmannin induced toxicity were not significant for any of the dosages in the 
given time frame.  
One consequence of the inhibition of autophagy is the accumulation of impaired organelles, 
proteins and other cell components [18]. This might lead to increased oxidative stress, 
mitochondrial dysfunction and protein aggregation, ultimately leading to cell death [83]. 
However these mechanisms may need a longer incubation time to develop their harmful 
potential, therefore we suggest that the time of the treatment (48h) might not have been long 
enough to activate the autophagy inhibition. A constant inhibition of autophagy over 72 hours 
or even longer [75] might affirm more outstanding differences in toxicity for the haplotypes.  
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5.1.4 H2O2 treatment     
Focusing the induction of oxidative stress, the cells were treated with 20 and 40 µM for 24h 
[68]. Even though we could observe a higher toxicity for the H1/H1 haplotype when 
compared to the H2/H2, both haplotypes developed a very high toxicity and a small 
statistical difference was only observed after treatment with the lower concentration of H2O2. 
The decrease of viable cells observed after H2O2 treatment can provide evidence of its 
highly potential of toxicity [25]. We speculate that in the LDH assay the 24h exposure time 
and the elected concentrations might have been too high to reveal the genotypes 
differences. The sensitivity for differences in LDH release might be increased by lower 
concentrations or reduced exposure time. Another fact that should be taking into 
consideration is the instability of H2O2 [74]. Even though the solutions were prepared 
immediately before application, a high variability of toxic impact is demonstrated by the error 
bars.  
5.1.5 Increased susceptibility of the H1/H1 haplotype to toxins and 
Parkinson’s disease 
After treatment with rotenone acute toxicity assessed by LDH assay after rotenone treatment 
was markedly higher in the H1/H1 MAPT haplotype  compared to H2/H2 , thus suggesting a 
higher susceptibility. The H1 haplotype increased risk of Parkinson’s disease [49], together 
with the dopaminergic neurodegeneration by the complex I impairment [60], suggests that 
the combination of MAPT genotype and biochemical stressor could possibly generate a 
higher risk for PD. The results of the epoxomicin treatment also indicate a higher 
susceptibility of the H1/H1 genotype by proteasome inhibition in hmNPC in the H1/H1 MAPT 
haplotype.  
At this time point, the reason for these higher susceptibilities is rather speculative. It could be 
related with an increased tau expression from the H1 haplotype, notably the 4R isoform [46], 
[62]. It has already been suggested that the aggregation of α­synuclein could be enhanced 
by an increased tau concentration due to its elevated expression levels [22], [37]. The 
oxidative damage resulted from rotenone exposure might also be related to the aggregation 
of α­synuclein [60]. In vivo experiments have already described that rotenone induces 
aggregated forms of α­synuclein in the substantia nigra, due to oxidative stress [60].  
The proteasome inhibitor, epoxomicin, binds to the 20S proteasome. Defects on this subunit 
can exceed the capacity of degradation of the UPS aggresome leading to the aggregation of 
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poorly degraded proteins [41]. This defect will promote protein aggregation in dopaminergic 
neurons [41]. Additionally, disruptions in proteasome function might influence the production 
of ROS and the oxidative damage [72]. Aggregated α­synuclein could inhibit proteasomal 
and autophagic pathway by binding to the proteasome and avoiding the formation of the 
autophagosome [63], [83]. In addition, the overexpression of tau could disturb the axonal 
transport of vesicles and organelles in neurons and cause defects in mitochondria [52], [64], 
[65]. 
In summary, these data suggest that combination of the H1 MAPT risk haplotype with the 
cellular impairments caused by treatment with rotenone or epoxomicin increases the 
susceptibility of the development of Parkinson’s disease. 
5.2 Expression of tau isoforms in different haplotypes 
The tau protein has 6 isoforms in the adult human brain; these isoforms are generated by 
alternative splicing and differ from each other by the number of inserts in its N-terminus and 
by the number of repeats in the C-terminal [11]. Since the different isoforms are expressed in 
distinct phases during the development, each of them is related to a physiological role [1]. In 
early stages of brain development and its embryonic phase the 3R tau is the primarily 
expressed isoform, while in the adult brain all six tau isoforms are available [11]. 3R tau 
isoforms do not bind as tightly as 4R tau isoforms to microtubules, further, tau 
phosphorylation interfere negatively to the amount of tau that binds on the C-terminal [11]. 
An attachment of 3R to 4R monomer or polymer is possible to happen, decreasing 4R tau 
association, however, at normal circumstances, unless the 3R binding was irreversible a 
decrease at the amount of 4R would not happen [1]. 
We could observe on our Western Blots a constant presence of the 1N4R tau isoform. In 
humans, the 1N4R tau isoform is the most abundant [80]. Another isoform constantly 
expressed in our assays was the human fetal tau protein isoform, the 0N3R. This isoform is 
expressed during fetal development [59] with the expression peak at mid gestation period 
and until birth [29]. 
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6 Conclusions 
This thesis had the purpose of comparing the susceptibility of hmNPC lines with different 
MAPT haplotypes, after exposure of toxins which provoke cellular dysfunctions associated 
with IPS. In addition, the development of protocols for evaluation of 3R and 4R tau isoforms  
to study tau isoform expression over distinct differentiation times in the different MAPT 
haplotypes was anticipated.  
The acute cell toxicity, assessed via LDH assay, revealed a higher toxin susceptibility for the 
H1/H1 genotype compared to the H2/H2 after treatment with rotenone and epoxomicin a 
complex I inhibitor and a proteasome inhibitor, respectively. These results suggest that the 
H1 risk-haplotype might be involved in mitochondrial and proteasomal dysfunction to IPS 
development. Further studies with autophagy inhibitor wortmannin and the inductor of 
oxidative stress H2O2 should be performed.  
The hmNPC lines, after one or two weeks of differentiation seem to express the 3R tau 
isoform more abundantly than the 4R isoform, however the assay is still in progress. Here, 
we suggest additional experiments. After optimization at the tau WB, we propose inducing 
toxicity in hmNPC at different times of differentiation, followed by LDH measurement and 
Western Blot to the different tau isoforms, in order to compare the 4R:3R after stress. 
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